Day: April 16, 2025

Completion of compulsory acquisition of remaining issued and outstanding shares of Avenir LNG Limited

Written by Customer Service on April 16, 2025. Posted in Mergers And Acquisitions.

London, April 16, 2025 – Reference is made to the stock exchange announcement of March 5, 2025, stating that Stolt-Nielsen Limited (Oslo Børs: SNI), through its subsidiary Stolt-Nielsen Gas Ltd. had resolved to proceed with a compulsory acquisition of the shares of Avenir LNG Limited (‘Avenir LNG’) not already owned by Stolt-Nielsen Gas Ltd. Stolt-Nielsen Limited is pleased to announce that the compulsory acquisition process has been successfully completed, and Avenir LNG is now fully owned by Stolt-Nielsen Gas Ltd. A request to have Avenir LNG delisted from Euronext N-OTC will be submitted, and it is expected that such delisting will occur shortly. Advisors DNB Markets, a part of DNB Bank ASA, acted as financial advisor to Stolt-Nielsen Limited, and Advokatfirmaet Thommessen AS acted as legal advisor to Stolt-Nielsen Limited, in connection...

Heineken N.V. reports on 2025 first quarter trading

Written by Customer Service on April 16, 2025. Posted in Earnings Releases And Operating Results.

Heineken N.V. reports on 2025 first quarter trading Amsterdam, 16 April 2025 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) announces First quarter performance as anticipated, full year outlook unchangedKey HighlightsRevenue €7,784 million, decreasing 4.9% Net revenue (beia) organic growth up 0.9%; per hectolitre increasing 3.3% Beer volume organic decrease of 2.1% Premium beer volume organic growth of 1.8%; Heineken® volume growth of 4.6% Outlook for the full year unchanged; operating profit (beia) expected to grow organically 4% to 8%CEO StatementDolf van den Brink, Chairman of the Executive Board / CEO, commented: “In the first quarter, we delivered a 0.9% organic increase in net revenue. As anticipated, primarily due to calendar-related factors, organic beer volume declined by 2.1%. Despite volatile consumer...

Heineken Holding N.V. reports on 2025 first quarter trading

Written by Customer Service on April 16, 2025. Posted in Earnings Releases And Operating Results.

Heineken Holding N.V. reports on 2025 first quarter trading Amsterdam, 16 April 2025 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) announces First quarter performance as anticipated, full year outlook unchangedKey HighlightsRevenue €7,784 million, decreasing 4.9% Net revenue (beia) organic growth up 0.9%; per hectolitre increasing 3.3% Beer volume organic decrease of 2.1% Premium beer volume organic growth of 1.8%; Heineken® volume growth of 4.6% Outlook for the full year unchanged; operating profit (beia) expected to grow organically 4% to 8%Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company.Financial SummaryThroughout this report figures refer to quarterly...

Vallourec Receives an Investment Grade Rating and Reports Positive Rating Actions by All Three Agencies

Written by Customer Service on April 16, 2025. Posted in Public Companies.

VALLOUREC RECEIVES AN INVESTMENT GRADE RATINGAND REPORTS POSITIVE RATING ACTIONS BY ALL THREE AGENCIES Meudon (France), April 16, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces several positive developments in its credit outlook from S&P Global, Moody’s Ratings and Fitch Ratings. Specifically:Fitch Ratings upgraded Vallourec from BB+ to BBB-, an Investment Grade rating, with a stable outlook. This marks Vallourec’s first Investment Grade rating since 2015. Moody’s Ratings upgraded Vallourec from Ba2 to Ba1 and maintained its positive outlook. S&P Global affirmed Vallourec’s BB+ long-term issuer credit rating and revised its outlook from neutral to positive.Fitch Ratings highlighted that “Vallourec’s business profile has improved over the past few years due to an optimized footprint, cost...

Santhera shares updates on commercial rollout of AGAMREE®

Written by Customer Service on April 16, 2025. Posted in Public Companies.

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding from National Health Service (NHS) England is now available for AGAMREE for the treatment of DMD, enabling prescribing in England to commence. This follows positive NICE (National Institute for Health and Care Excellence) final guidance for AGAMREE announced on January 16, 2025 and initial sales already achieved in Scotland and Wales. In addition, Santhera notes that Kye Pharmaceuticals, sub-licensee of its commercialization partner Catalyst Pharmaceuticals, has received acceptance by Health Canada for the New Drug Submission for AGAMREE with Priority Review. This potentially paves the way for the therapy to become the first approved...

Technip Energies awarded a FEED contract for Jet Zero’s Sustainable Aviation Fuel project in Australia

Written by Customer Service on April 16, 2025. Posted in Public Companies.

Technip Energies (PARIS:TE) has been awarded a Front-End Engineering Design (FEED) contract by Jet Zero Australia Pty Ltd (Jet Zero) for Project Ulysses, a bioethanol to sustainable aviation fuel (SAF) project located in Townsville, Australia. The FEED covers an extensive package of engineering activities, documentation and planning to refine the cost estimate for the project and develop detailed timelines. The project aims to produce 102 million liters of SAF and 11 million litres of renewable diesel annually by 2028 using Australian bioethanol and technologies from Technip Energies and LanzaJet. Technip Energies’ Hummingbird® technology converts the bioethanol to sustainable ethylene and LanzaJet’s alcohol-to-jet technology transforms the ethylene to SAF. Sylvain Cabalery, SVP Sustainable Fuels, Chemicals & Circularity at Technip...

Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond

Written by Customer Service on April 16, 2025. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere kantonale Nachlassbehörde) (the Court) in relation to its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, which matured on January 17, 2025, was held yesterday and that the Court approved the amendments of the Bond terms decided at the bondholder meeting held on February 25, 2025. The amended terms will become effective, if no appeal is filed against the court decision, within 30 days from the official publication of the written statement of the grounds. All information related to the meeting can be found at the following link: www.idorsia.com/CB2025. Approving...

Believe’s majority shareholder, Upbeat BidCo, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the shares it does not hold.

Written by Customer Service on April 16, 2025. Posted in Mergers And Acquisitions.

Believe’s majority shareholder, Upbeat BidCo, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the shares it does not hold.Offer at a price of 15.30 euros per share, reflecting premiums of +2.9%, +4.4%, +7.5% and +6.0%, respectively, over the 30-day, 60-day, 120-day and 180-day volume-weighted average prices as of April 14, 2025. The Board of Believe has set up an ad hoc Committee made up of the three independent directors and appointed Finexsi as independent expert.Paris, April 16, 2025 – Upbeat BidCo announces its intention to file today a public buy-out offer (offre publique de retrait) (the “Offer”), followed by a squeeze-out (retrait obligatoire) (the “Squeeze-Out”), on the Believe shares it does not hold directly or by assimilation pursuant to article L. 233‑9 of the French Commercial Code. The...

ASML reports €7.7 billion total net sales and €2.4 billion net income in Q1 2025

Written by Customer Service on April 16, 2025. Posted in Earnings Releases And Operating Results.

ASML reports €7.7 billion total net sales and €2.4 billion net income in Q1 2025 2025 total net sales expected to be between €30 billion and €35 billion VELDHOVEN, the Netherlands, April 16, 2025 – Today, ASML Holding NV (ASML) has published its 2025 first-quarter results.Q1 total net sales of €7.7 billion, gross margin of 54.0%, net income of €2.4 billion Quarterly net bookings in Q1 of €3.9 billion2 of which €1.2 billion is EUV ASML expects Q2 2025 total net sales between €7.2 billion and €7.7 billion, and a gross margin between 50% and 53%3 ASML continues to expect 2025 total net sales to be between €30 billion and €35 billion, with a gross margin between 51% and 53%(Figures in millions of euros unless otherwise indicated) Q4 2024 Q1 2025Total net sales 9,263 7,742…of which Installed...

Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025

Written by Customer Service on April 16, 2025. Posted in Public Companies.

Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today scientific presentations on Basilea’s clinical-stage novel antifungal fosmanogepix given at ESCMID Global 2025, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 11 to 15, 2025 in Vienna, Austria. Further presentations covered the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®). Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “Invasive fungal infections are an increasing global health problem and novel antifungals are urgently needed. To date more than 250 patients suffering from difficult-to-treat...

Day: April 16, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals